NTRA Logo

Natera, Inc. (NTRA) 

NASDAQ$148.22
Market Cap
$20.04B
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
741 of 924
Rank in Industry
41 of 49

NTRA Insider Trading Activity

NTRA Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$000
Sells
$164,783,147128100

Related Transactions

Chapman Rowan Edirector0$03$1.16M$-1.16M
Marcus Gail Boxerdirector0$04$2.71M$-2.71M
Baynes Roy D.director0$01$5.44M$-5.44M
Fesko JohnPRESIDENT, CHIEF BUS. OFFICER0$014$5.52M$-5.52M
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICER0$013$9.61M$-9.61M
BOTHA ROELOFdirector0$01$14.79M$-14.79M
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS0$016$15.37M$-15.37M
Brophy Michael BurkesCHIEF FINANCIAL OFFICER0$032$16.88M$-16.88M
Sheena JonathanCO-FOUNDER0$019$18.36M$-18.36M
Rabinowitz MatthewEXECUTIVE CHAIRMAN0$05$35.57M$-35.57M
Chapman Steven LeonardCEO AND PRESIDENT0$021$51.31M$-51.31M

About Natera, Inc.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro â€¦

Insider Activity of Natera, Inc.

Over the last 12 months, insiders at Natera, Inc. have bought $0 and sold $164.78M worth of Natera, Inc. stock.

On average, over the past 5 years, insiders at Natera, Inc. have bought $3.98M and sold $94.42M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 219,820 shares for transaction amount of $6.32M was made by Rabinowitz Matthew () on 2022‑05‑12.

List of Insider Buy and Sell Transactions, Natera, Inc.

2025-03-14SaleRabinowitz MatthewEXECUTIVE CHAIRMAN
50,000
0.0369%
$147.71$7.39M+0.35%
2025-03-12SaleMarcus Gail Boxerdirector
4,000
0.003%
$147.69$590,773+0.60%
2025-03-05SaleChapman Steven LeonardCEO AND PRESIDENT
87,272
0.0626%
$143.40$12.52M-4.34%
2025-03-05SaleMoshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
6,000
0.0043%
$143.29$859,734-4.34%
2025-02-26SaleSheena JonathanCO-FOUNDER
5,600
0.0042%
$160.47$898,609-11.49%
2025-02-06SaleFesko JohnPRESIDENT, CHIEF BUS. OFFICER
663
0.0005%
$177.77$117,862-10.58%
2025-02-06SaleMoshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
1,632
0.0012%
$177.77$290,121-10.58%
2025-02-03SaleBrophy Michael BurkesCHIEF FINANCIAL OFFICER
43,502
0.0329%
$176.88$7.69M-9.46%
2025-01-31SaleSheena JonathanCO-FOUNDER
163
0.0001%
$176.60$28,786-8.79%
2025-01-31SaleBrophy Michael BurkesCHIEF FINANCIAL OFFICER
2,286
0.0017%
$175.98$402,288-8.79%
2025-01-31SaleBrophy Michael BurkesCHIEF FINANCIAL OFFICER
1,886
0.0014%
$176.60$333,068-8.79%
2025-01-29SaleRabinowitz MatthewEXECUTIVE CHAIRMAN
6,003
0.0045%
$165.87$995,716-0.93%
2025-01-29SaleSheena JonathanCO-FOUNDER
1,054
0.0008%
$165.87$174,827-0.93%
2025-01-29SaleChapman Steven LeonardCEO AND PRESIDENT
13,685
0.0102%
$165.87$2.27M-0.93%
2025-01-29SaleRABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICER
4,773
0.0036%
$165.87$791,694-0.93%
2025-01-29SaleFesko JohnPRESIDENT, CHIEF BUS. OFFICER
4,030
0.003%
$165.87$668,454-0.93%
2025-01-29SaleMoshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
5,201
0.0039%
$165.87$862,688-0.93%
2025-01-29SaleBrophy Michael BurkesCHIEF FINANCIAL OFFICER
4,335
0.0032%
$165.87$719,044-0.93%
2025-01-27SaleBrophy Michael BurkesCHIEF FINANCIAL OFFICER
1,442
0.0011%
$161.87$233,417+1.20%
2025-01-24SaleBrophy Michael BurkesCHIEF FINANCIAL OFFICER
946
0.0007%
$171.98$162,689-0.39%
Total: 667
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Rabinowitz MatthewEXECUTIVE CHAIRMAN
2365415
1.7497%
$350.6M173+52.44%
BOTHA ROELOFdirector
1224787
0.906%
$181.54M22+4.55%
HEALY JAMESdirector
0
0%
$032<0.0001%
Steuart Johndirector
0
0%
$011<0.0001%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$53,318,456
175
15.57%
$432.04M
$38,597,637
114
658.88%
$2.47M
$1,590,764
16
3.90%
$55.22M
Natera, Inc.
(NTRA)
$26,663,659
7
-12.13%
$20.04B
$151,252
6
-58.10%
$11.58M

NTRA Institutional Investors: Active Positions

Increased Positions323+56.77%17M+14%
Decreased Positions256-44.99%13M-10.88%
New Positions137New3MNew
Sold Out Positions43Sold Out579,247Sold Out
Total Postitions636+11.78%127M+3.12%

NTRA Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$1.92M9.33%12.32M+879,463+7.69%2024-12-31
Blackrock, Inc.$1.43M6.96%9.18M+947,457+11.51%2024-12-31
Price T Rowe Associates Inc /Md/$1.05M5.11%6.74M+4M+134.88%2024-12-31
Jpmorgan Chase & Co$1.04M5.08%6.7M+2M+44.68%2024-12-31
Farallon Capital Management Llc$689,514.003.36%4.43M-125,700-2.76%2024-12-31
Duquesne Family Office Llc$554,966.002.7%3.57M00%2024-12-31
Wellington Management Group Llp$504,118.002.46%3.24M+439,778+15.71%2024-12-31
Fred Alger Management, Llc$469,542.002.29%3.02M-994,184-24.78%2024-12-31
State Street Corp$465,365.002.27%2.99M-503,369-14.4%2024-12-31
Rtw Investments, Lp$403,495.001.97%2.59M00%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.